EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Protocol for pragmatic randomized clinical trial to evaluate the completion of treatment of latent Mycobacterium tuberculosis infection with Isoniazid in the 300 mg formulation

João Paulo Cola iD, Thiago Nascimento do Prado, Bárbara Almeida Campos, Bárbara Juliana Pinheiro Borges, Bárbara Manuella Cardoso Sodré Alves, Sonia Vivian de Jezus iD, Carolina Maia Martins Sales, Wildo Navegantes de Araújo, Noemia Urruth Leão Tavares, Ethel Leonor Noia Maciel iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0281638 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2023. Verfasst von João Paulo Cola und 9 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program in Collective Health, Laboratory of Epidemiology, Universidade Federal do Espírito Santo, Vitória, Espírito Santo, Brazil. Hauptthemen laut MEDLINE: Isoniazid, Latent Tuberculosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

It is essential to strengthen the treatment of latent tuberculosis infection (LTBI) to break the chain of transmission. The drug used worldwide for the treatment of LTBI is Isoniazid. A clinical trial conducted in Brazil has demonstrated the bioequivalence of Isoniazid in the 300 mg formulation with 3 tablets in the 100 mg formulation. Further studies are needed to evaluate the completion of treatment with Isoniazid 300 mg single tablet.

Objective

Describing a protocol for a clinical trial to evaluate the completion of treatment of LTBI with the drug Isoniazid in 300 mg tablet formulation compared to the use of Isoniazid in 100 mg tablet formulation.

Methods

This is a pragmatic, multicenter, randomized, open-label clinical trial registered on the Rebec RBR-2wsdt6 platform. Individuals 18 years of age or older with an indication for treatment of LTBI will be included, with only 1 individual per family nucleus. Individuals whose index case of active TB is categorized as retreatment, multidrug-resistant and extremely resistant, individuals transferred from the original center two or more weeks after the onset of treatment, and persons deprived of liberty will be excluded. The study intervention will be the treatment of LTBI with 1 tablet of Isoniazid 300 mg. The control group will receive the treatment of LTBI with 3 tablets of Isoniazid 100 mg. Follow-up will be performed at month 1, month 2 and at the end of treatment. The primary outcome will be completion of treatment.

Conclusion

It is expected that with the treatment with the 300 mg formulation, more patients will complete the treatment based on the complexity index of pharmacotherapy. Our study intends to substantiate theoretical and operational strategies that respond to the demand for incorporation of a new formulation of the drug for the treatment of LTBI in the Unified Health System network.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoniazidLatent TuberculosisHumansAdolescentAdultAntitubercular AgentsRetreatmentBrazilRandomized Controlled Trials as TopicMulticenter Studies as TopicPragmatic Clinical Trials as Topic

Substanzen

IsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • Postgraduate Program in Collective Health, Laboratory of Epidemiology, Universidade Federal do Espírito Santo, Vitória, Espírito Santo, Brazil.
  • Postgraduate Program in Pharmaceutical Sciences, Universidade de Brasília, Brasília, Distrito Federal, Brazil.
  • Postgraduate Program in Tropical Medicine, Universidade de Brasília, Brasília, Distrito Federal, Brazil.

ORCID-Profile: João Paulo Cola, Sonia Vivian de Jezus, Ethel Leonor Noia Maciel

Zitieren

APA

Cola, J. P., Prado, T. N. D., Campos, B. A., Borges, B. J. P., Alves, B. M. C. S., Jezus, S. V., Sales, C. M. M., Araújo, W. N., Tavares, N. U. L., & Noia Maciel, E. L. (2023). Protocol for pragmatic randomized clinical trial to evaluate the completion of treatment of latent Mycobacterium tuberculosis infection with Isoniazid in the 300 mg formulation. PLOS ONE. https://doi.org/10.1371/journal.pone.0281638

Vancouver

Cola JP, Prado TND, Campos BA, Borges BJP, Alves BMCS, Jezus SV, et al. Protocol for pragmatic randomized clinical trial to evaluate the completion of treatment of latent Mycobacterium tuberculosis infection with Isoniazid in the 300 mg formulation. PLOS ONE. 2023. doi:10.1371/journal.pone.0281638

BibTeX
@article{Cola2023,
  author = {Cola, João Paulo and Prado, Thiago Nascimento do and Campos, Bárbara Almeida and Borges, Bárbara Juliana Pinheiro and Alves, Bárbara Manuella Cardoso Sodré and Jezus, Sonia Vivian de and Sales, Carolina Maia Martins and Araújo, Wildo Navegantes de and Tavares, Noemia Urruth Leão and Noia Maciel, Ethel Leonor},
  title = {Protocol for pragmatic randomized clinical trial to evaluate the completion of treatment of latent Mycobacterium tuberculosis infection with Isoniazid in the 300 mg formulation},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0281638}
}
Kostenlos starten →